Pharmaceutical R&D Services

One-Stop Shop for Stroke Drug Development and Preclinical Studies

Our services include the advancement of basic stroke research, experimental modeling and preclinical drug studies, providing researchers with a comprehensive platform to develop new therapies.

What Are the Current Pain Points in Stroke Drug Development?

Acute ischemic stroke treatments are limited and ineffective.
Lack of fast-acting medications for post-stroke depression (PSD) and anxiety (PSA).
Multicenter structure leads to heterogeneity in preclinical studies.
Uncertainty about stem cell therapy in stroke treatment.
Lack of validated biomarkers.
Blood-brain barrier penetration challenges, where drugs need to overcome the blood-brain barrier to effectively reach brain lesions.
Drug toxicity and safety issues.

These pain points suggest that despite some promising research and drug candidates, stroke drug development still faces significant challenges and requires further research and innovation to overcome existing barriers.

What Preclinical Work Is Needed for the Development of Stroke Therapies?

In Vitro Experiment

Pharmacodynamic Studies

Safety pharmacology Studies

Animal Experimentation

Pharmacokinetic Studies

What Are All the Molecular Types of Stroke Drugs?

Small-Molecule Antiplatelet Drugs	Cyclooxygenase inhibitors Phosphodiesterase inhibitors ADP receptor antagonists Membrane protein IIb/IIIa (GP IIb/IIIa) receptor antagonists Adenosine receptor antagonists 5-hydroxytryptamine (5-HT) receptor antagonists
Neuroprotective Peptides	Interfering Peptides Arginine-Rich Peptides Blood-Brain Barrier Shuttle Peptides Synthetic Peptides
Monoclonal Antibodies for Stroke	Anti-Myelin-Associated Protein Antibodies Anti-GluN1 Antibodies Anti-Cell Adhesion Molecule and Anti-Cytokine Antibodies
Neuroprotective Agents Against Stroke	Glutamate Receptor Antagonists Free-radical Scavengers and Antioxidants Calcium Channel Blockers Sodium Channel Blockers Anti-inflammatory Stroke Therapies GABA Receptor Agonists Magnesium Therapies C-Jun N-terminal Kinase Inhibitors Small Molecule Erythropoietin Mimetics PPAR Agonists Blood Glutamate Scavengers
Stroke Thrombolytics	Fibrin-specific thrombolytic agents of bacterial origin Thrombolytic agents of various eukaryotic origin Thrombolytic agents of non-mammalian origin
Anticoagulant Drugs for Stroke	Heparins Heparinoids Oral anticoagulant drugs Thrombin inhibitors
Stem Cell-Based Therapy	Mesenchymal Stem Cell-Based Therapies Neural Stem Cell Therapies

These drugs play an important role in the treatment of different types and stages of stroke. We can provide customized therapeutic development services for stroke treatment based on your experimental needs.

Find the Right Comprehensive Stroke Models for Your Study

Mouse Models

Transient MCAO (tMCAO) in mouse
Permanent MCAO (pMCAO) in mouse
Photochemically-induced stroke mouse model

Rat Models

Transient MCAO (tMCAO) in rat
Permanent MCAO (pMCAO) in rat
Photochemically-induced rat stroke model
Endothelin-1 (ET-1) induced ischemia stroke in rat

NHP Models

ET-1 induced MCAO model in NHPs
Cynomolgus MCAO model
Rhesus monkeys endovascular stroke model

Porcine Models

Porcine ischemic stroke model

Canine Models

Canine pMCAO model

Explore Our Models

Advantages of Our Stroke Model

Reliability Our model depicts the most accurate and up-to-date representations of the human stroke state.
Precision Our outcome tests designed specifically for stroke animal models can precisely assess critical aspects of the stroke state such as mood, cognition, sensorimotor deficits, learning and memory function.
Quality Rigorous post-operative care protocols that maximize survival and increase the extent and duration of deficits

What Are All the Causative Factors That Lead to Stroke?

Stroke often occurs as a result of a combination of factors. These factors can interact with each other, gradually aggravating the condition and eventually leading to a stroke.

What Biomarkers Would You Like to Explore?

Stroke-Related Protein Biomarkers	S100 calcium binding protein B (S-100B), neuron-specific enolase (NSE), myelin basic protein (MBP), glial fibrillary acidic protein (GFAP)
Stroke-Related RNA Biomarkers	ARG1, LY96, MMP9, CCR7, INPP5D, ITA4, NAV1, CREM, PELI1, ZAK, CD46, CCL2, IL8, LAG3, HLA-DQA1
Stroke-Related Metabolite Biomarkers	Glutamate, glutamine, phenylalanine, tyrosine, homocysteine, methionine, tryptophan, aspartate, alanine, proline, pyroglutamate
Stroke-Related Lipid Biomarkers	Triglyceride-to-high-density-lipoprotein cholesterol ratio, lipoprotein (a), total cholesterol, low-density lipoprotein-cholesterol
Stroke Biomarker Panels	In stroke, biomarker groups can provide information about atherosclerosis, thrombosis, inflammation, oxidative stress, endothelial damage, blood-brain barrier disruption, and cerebral ischemia.

Potential Value of Biomarkers

Potential for early diagnosis of stroke
Distinguishing between ischemic and hemorrhagic stroke
Predicting the risk of hemorrhagic conversion in ischemic stroke
For personalized treatment

By integrating genomics, transcriptomics, proteomics and metabolomics, we help our clients to systematically reflect the complex pathophysiological processes of ischemic stroke, which helps to improve the accuracy of early diagnosis. For example, mass spectrometry has demonstrated high sensitivity and specificity in the discovery of metabolic and protein biomarkers associated with stroke, helping to reveal the metabolic changes in stroke.

Subscribe for More Information on Stroke Research

Whether you want to learn about advances in new drug development, pharmacodynamic modeling and evaluation, rapid-acting drug development, stroke mechanisms and treatment strategies, or stroke emergency and prevention research on stroke, subscribe to us.

Our Advantages

Professionals

Deep expertise and experience in vascular research and development.
Well-equipped

Our fully equipped laboratories have comprehensive capabilities from initial screening to candidate selection.
Customization

Flexible approach with easy access to our global network of specialized laboratories. State-of-the-art technology provides you with a fully customized service.
After Sales Service

Solving any problems or concerns that customers may have and ensuring the proper functioning of the product or service.

Customers Often Look For

FAQs

How to Construct an In Vitro Model of the Blood-Brain Barrier (BBB)?

The construction of in vitro models of the BBB usually involves cells of different species, including human brain microvascular endothelial cell lines (e.g., hCMEC/D3), and primary cerebrovascular endothelial cells from rats and mice. These cells can be cultured alone or co-cultured with other cell types (e.g. astrocytes, pericytes) to mimic the structure and function of the BBB in vivo. The co-culture model enables better expression of tight junction proteins (e.g., Claudin-5 and ZO-1) and increased trans-endothelial electrical resistance (TEER), thus more closely approximating the properties of the BBB in vivo.

What Is the Difference Between Static BBB Models and Dynamic BBB?

BBB in vitro models can be categorized into static and dynamic models. Static models typically use the Transwell system to mimic the BBB by culturing monolayers or co-cultures of cells under static conditions; however, these models do not fully mimic the shear stresses generated by blood flow in vivo, and therefore may have a weaker barrier function. Dynamic models, on the other hand, enhance the barrier effect of the BBB by simulating blood flow shear stress, such as the BBB-on-a-chip model constructed using microfluidic chip technology, which enables perfusion and mimics mechanical signals to more realistically reflect the properties of the BBB in vivo.

What Are the Available Laboratory Animals?

Non-human primates (NHP), rodents, rabbits, pigs, dogs.

What Are the Available Animal Models of Ischemic Stroke?

Four-vessel occlusion (4-VO) model, two-vessel occlusion (2-VO) model, complete global brain ischemia models, endovascular filament model of middle cerebral artery occlusion (MCAO), middle cerebral artery occlusion (MCAO) model by transcranial electrocoagulation, embolic stroke models, endothelin-1 (ET-1) induced ischemic stroke model, photothrombotic stroke model.

What Are the Usual Types of Neuroprotective Agents?

There is a wide variety of neuroprotective agents under development, including the following main categories: calcium channel blockers, glutamate receptor antagonists, gamma-aminobutyric acid (GABA) receptor agonists, free radical scavengers, cell membrane stabilizers, mitochondrial protectors, anti-inflammatory agents.

How to Improve BBB Efficiency in CNS?

Polymeric nanoparticles, nanocapsule encapsulation of liposomes, nanoparticle-mediated transnasal drug delivery systems, viral-based gene delivery systems, exosome-based drug delivery systems. These strategies can be used to improve BBB efficiency and thus enhance drug delivery and efficacy in the CNS. However, each approach has its advantages and disadvantages and needs to be selected and optimized based on specific disease and drug properties.

Additional Links and Resources

Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.

Quick Links

Home Services Therapeutic Areas

Resources About us Contact us Careers

Inquiry Basket

Delete selected Check Out